Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,34268908,AUC0-72h,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [h·ml],7649,4157,DB01611,Hydroxychloroquine
,34268908,AUC0-72h,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [h·ml],8429,4158,DB01611,Hydroxychloroquine
,34268908,Cmax,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [ml],448,4159,DB01611,Hydroxychloroquine
,34268908,Cmax,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [ml],451.5,4160,DB01611,Hydroxychloroquine
,32558210,plasma clearance,Median [IQR] plasma clearance of the Seraph for chloroquine/hydroxychloroquine was 1.71 [0.51-4.38] mL/min/1.79 [0.21-3.68] mL/min respectively.,Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558210/),[ml] / [min],1.71,6935,DB01611,Hydroxychloroquine
,32558210,plasma clearance,Median [IQR] plasma clearance of the Seraph for chloroquine/hydroxychloroquine was 1.71 [0.51-4.38] mL/min/1.79 [0.21-3.68] mL/min respectively.,Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558210/),[ml] / [min],1.79,6936,DB01611,Hydroxychloroquine
,24991836,overall response rate (ORR),"The overall response rate (ORR) for dogs with lymphoma was 93.3%, with median progression-free interval (PFI) of 5 mo.",Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991836/),%,93.3,8456,DB01611,Hydroxychloroquine
more,2757893,terminal elimination half-life,"2. The terminal elimination half-life of hydroxychloroquine is more than 40 days, thus blood and urine samples were collected for 5 months following each dose to characterise adequately the terminal elimination phase and obtain accurate estimates of the areas under the concentration-time curves.",Bioavailability of hydroxychloroquine tablets in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757893/),d,40,15632,DB01611,Hydroxychloroquine
,2757893,fraction of the oral dose absorbed,"3. The mean (+/- s.d.) fraction of the oral dose absorbed, estimated from the blood and urine data, was 0.74 (+/- 0.13).",Bioavailability of hydroxychloroquine tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757893/),,0.74,15633,DB01611,Hydroxychloroquine
,33519466,maximum concentration (C max),Results demonstrated that the maximum concentration (C max) of HCQ was 292.33 ng/mL in blood and 36.90 ng/mL in plasma after single dose of 3 mg/kg.,Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),[ng] / [ml],292.33,27129,DB01611,Hydroxychloroquine
,33519466,maximum concentration (C max),Results demonstrated that the maximum concentration (C max) of HCQ was 292.33 ng/mL in blood and 36.90 ng/mL in plasma after single dose of 3 mg/kg.,Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),[ng] / [ml],36.90,27130,DB01611,Hydroxychloroquine
,33519466,area under curve (AUC0-∞),"The value of area under curve (AUC0-∞) was determined as 5,978.94 and 363.31 h* ng/mL for the blood and plasma, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),[h·ng] / [ml],"5,978.94",27131,DB01611,Hydroxychloroquine
,33519466,area under curve (AUC0-∞),"The value of area under curve (AUC0-∞) was determined as 5,978.94 and 363.31 h* ng/mL for the blood and plasma, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),[h·ng] / [ml],363.31,27132,DB01611,Hydroxychloroquine
,33519466,tissue-to-plasma concentration ratio,"The tissue-to-plasma concentration ratio and the tissue-to-blood concentration ratio for lung were found to be time-dependent with 267.38 and 5.55 at 120 h postdose, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),,267.38,27133,DB01611,Hydroxychloroquine
,33519466,tissue-to-blood concentration ratio,"The tissue-to-plasma concentration ratio and the tissue-to-blood concentration ratio for lung were found to be time-dependent with 267.38 and 5.55 at 120 h postdose, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),,5.55,27134,DB01611,Hydroxychloroquine
,33519466,elimination rate constant (ke),The estimated elimination rate constant (ke) for a typical monkey was 0.236 h-1.,Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),1/[h],0.236,27135,DB01611,Hydroxychloroquine
,33519466,volume of distribution in central (Vc/F),"The volume of distribution in central (Vc/F) and other two peripheral compartments (Vb/F and Vl/F) were 114, 2.68, and 5.55 L, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),l,114,27136,DB01611,Hydroxychloroquine
,33519466,Vb/F,"The volume of distribution in central (Vc/F) and other two peripheral compartments (Vb/F and Vl/F) were 114, 2.68, and 5.55 L, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),l,114,27137,DB01611,Hydroxychloroquine
,33519466,Vl/F,"The volume of distribution in central (Vc/F) and other two peripheral compartments (Vb/F and Vl/F) were 114, 2.68, and 5.55 L, respectively.",Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33519466/),l,5.55,27138,DB01611,Hydroxychloroquine
,3179169,Half-life,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),d,40,31464,DB01611,Hydroxychloroquine
,3179169,mean residence time,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),d,40,31465,DB01611,Hydroxychloroquine
,3179169,volumes of distribution,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),l,"5,522",31466,DB01611,Hydroxychloroquine
,3179169,volumes of distribution,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),l,"44,257",31467,DB01611,Hydroxychloroquine
,3179169,clearance,"The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),[ml] / [min],667,31468,DB01611,Hydroxychloroquine
,3179169,clearance,"The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),[ml] / [min],96,31469,DB01611,Hydroxychloroquine
,3179169,Blood to plasma concentration ratios,Blood to plasma concentration ratios were not constant (mean +/- s.d.: 7.2 +/- 4.2).,A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),,7.2,31470,DB01611,Hydroxychloroquine
,8373715,(R)/(S) ratio,"In all patients, the blood concentration of (R)-hydroxychloroquine exceeded that of the (S)-enantiomer, the mean (R)/(S) ratio being 2.2 (range 1.6-2.9).",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,2.2,32342,DB01611,Hydroxychloroquine
,8373715,(R)/(S) ratio,"A similar excess of (R)-hydroxychloroquine was found in the plasma, the mean (R)/(S) ratio being 1.6 (range 1.2-1.9).",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,1.6,32343,DB01611,Hydroxychloroquine
,8373715,blood concentration ratio (R)/(S),The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine.,Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,0.45,32344,DB01611,Hydroxychloroquine
,8373715,blood concentration ratio (R)/(S),The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine.,Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,0.56,32345,DB01611,Hydroxychloroquine
,8373715,renal clearance from blood,"(S)-hydroxychloroquine had a mean (+/- s.d.) renal clearance from blood of 41 +/- 11 ml min-1, approximately twice that of (R)-hydroxychloroquine.",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),[ml] / [min],41,32346,DB01611,Hydroxychloroquine
,32639233,Whole blood concentrations,Whole blood concentrations of 13.5 µmol/L (95% credible interval 10.1-17.7) were associated with 1% mortality.,Concentration-dependent mortality of chloroquine in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32639233/),[μM] / [l],13.5,43719,DB01611,Hydroxychloroquine
,10630270,elimination half-life,Plasma hydroxychloroquine level was 29.40 mumol/L (9.87 mg/L) 2 hours after ingestion and the elimination half-life of hydroxychloroquine was 22 hours.,Hydroxychloroquine overdose: toxicokinetics and management. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630270/),h,22,46844,DB01611,Hydroxychloroquine
,19188392,clearance,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),[l] / [h],15.5,51102,DB01611,Hydroxychloroquine
,19188392,central,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),[l] / [h],15.5,51103,DB01611,Hydroxychloroquine
,19188392,central,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),l,733,51104,DB01611,Hydroxychloroquine
,19188392,peripheral volumes of distribution,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),l,"1,630",51105,DB01611,Hydroxychloroquine
,32915766,flow rate,"HCQ, DCQ and DDCQ were chromatographically separated on a biphenyl column with gradient elution, at a flow rate of 500 μL/min.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),[μl] / [min],500,51311,DB01611,Hydroxychloroquine
,32915766,analysis time,The analysis time was 8 min.,Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),min,8,51312,DB01611,Hydroxychloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,80,51313,DB01611,Hydroxychloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,81,51314,DB01611,Hydroxychloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,78,51315,DB01611,Hydroxychloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,62,51316,DB01611,Hydroxychloroquine
,2055762,maximum daily dosage,Retinopathy can be avoided by observing a maximum daily dosage of 3.5-4 mg/kg ideal body weight for chloroquine and 6-6.5 mg/kg for hydroxychloroquine.,[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055762/),,3,67745,DB01611,Hydroxychloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),1/[h],9.3,68470,DB01611,Hydroxychloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),l,860.8,68471,DB01611,Hydroxychloroquine
,32968954,central compartment volume,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),l,860.8,68472,DB01611,Hydroxychloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68473,DB01611,Hydroxychloroquine
,32968954,central compartment volume,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68474,DB01611,Hydroxychloroquine
,32968954,clearance,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68475,DB01611,Hydroxychloroquine
,32968954,bioavailability factor,The bioavailability factor was fixed to 0.74 based on previously published models.,Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),,0.74,68476,DB01611,Hydroxychloroquine
,1545355,fraction absorbed,"The mean fraction absorbed (+/- SD) was 0.67 +/- 0.12, which was not significantly different from that reported previously in a conventional bioavailability study (p = 0.22).",Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),,0.67,84587,DB01611,Hydroxychloroquine
,1545355,absorption half-life,The mean absorption half-life was calculated to be 4.0 +/- 1.3 h.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),h,4.0,84588,DB01611,Hydroxychloroquine
,1545355,lag time before absorption commenced,The mean lag time before absorption commenced was 0.57 +/- 0.30 h.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),h,0.57,84589,DB01611,Hydroxychloroquine
,1545355,fraction of the dose absorbed,The fraction of the dose absorbed ranged from 0.44 to 0.86.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),,0.44 to 0.86,84590,DB01611,Hydroxychloroquine
,8156285,fraction absorbed,The mean fraction absorbed from the tablet was 0.79 (range 0.39 to 1.27).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),,0.79,96933,DB01611,Hydroxychloroquine
,8156285,absorption lag-time,The mean absorption lag-time was 1.3 h (range 0.5 to 3.7 h) and the mean time for 50% absorption was 4.3 h (range 1.9 to 10.3 h).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),h,1.3,96934,DB01611,Hydroxychloroquine
,8156285,time for 50% absorption,The mean absorption lag-time was 1.3 h (range 0.5 to 3.7 h) and the mean time for 50% absorption was 4.3 h (range 1.9 to 10.3 h).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),h,4.3,96935,DB01611,Hydroxychloroquine
,29207305,flow rate,"The chromatographic separation and detection of analytes were achieved on a reversed phase Thermo Aquasil C18 (50×4.6mm, 3μ) column, with gradient elution using 0.2% formic acid and 0.1% formic acid in methanol as mobile phase at a flow rate of 0.5mL/min.",Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29207305/),[ml] / [min],0.5,101802,DB01611,Hydroxychloroquine
,30255310,apparent volume of distribution,The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h.,Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255310/),[l] / [70·kg],1850,107257,DB01611,Hydroxychloroquine
,30255310,apparent clearance,The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h.,Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255310/),[l] / [h],51,107258,DB01611,Hydroxychloroquine
,27747530,relative bioavailability,The relative bioavailability was 109.5% (according to AUC0-60d) and 110.7% (according to AUC0-∝).,Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27747530/),%,109.5,117729,DB01611,Hydroxychloroquine
,27747530,relative bioavailability,The relative bioavailability was 109.5% (according to AUC0-60d) and 110.7% (according to AUC0-∝).,Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27747530/),%,110.7,117730,DB01611,Hydroxychloroquine
,24991838,progression-free survival,The median progression-free survival in 13 melanoma patients treated with HCQ 1200mg/d in combination with TEM was 3.5 mo.,Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991838/),mo,3.5,123535,DB01611,Hydroxychloroquine
,32866424,overall survival,Median overall survival was 16 months (range 2-32).,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,16,126667,DB01611,Hydroxychloroquine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126668,DB01611,Hydroxychloroquine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126669,DB01611,Hydroxychloroquine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126670,DB01611,Hydroxychloroquine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126671,DB01611,Hydroxychloroquine
,20334568,concentrations,"Mean concentrations of HCQ in adenoid tissue of subjects treated with 400 and 800 mg were 87,210 +/- 17,817 and 167,472 +/- 93,793 ng/g, respectively.",Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20334568/),,"87,210",135795,DB01611,Hydroxychloroquine
,20334568,concentrations,"Mean concentrations of HCQ in adenoid tissue of subjects treated with 400 and 800 mg were 87,210 +/- 17,817 and 167,472 +/- 93,793 ng/g, respectively.",Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20334568/),,"167,472",135796,DB01611,Hydroxychloroquine
,14639053,bioavailability,"The population estimate of bioavailability of 0.75 (0.07), n = 9, was consistent with literature values.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),,0.75,137772,DB01611,Hydroxychloroquine
,14639053,Cl,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),[l] / [h],9.9,137773,DB01611,Hydroxychloroquine
,14639053,V,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),l,605,137774,DB01611,Hydroxychloroquine
,14639053,ka,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),1/[hours],0.77,137775,DB01611,Hydroxychloroquine
,14639053,t(tag),"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),h,0.44,137776,DB01611,Hydroxychloroquine
,33259916,plasma concentrations,"Median (interquartile range) HCQ plasma concentrations were 0.09 (0.06-0.14) mg/L and 0.07 (0.05-0.08) mg/L for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],0.09,143519,DB01611,Hydroxychloroquine
,33259916,plasma concentrations,"Median (interquartile range) HCQ plasma concentrations were 0.09 (0.06-0.14) mg/L and 0.07 (0.05-0.08) mg/L for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],0.07,143520,DB01611,Hydroxychloroquine
,33259916,ELF,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],3.74,143521,DB01611,Hydroxychloroquine
,33259916,ELF,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),,1.81,143522,DB01611,Hydroxychloroquine
,33259916,concentrations,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],3.74,143523,DB01611,Hydroxychloroquine
,33259916,concentrations,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),,1.81,143524,DB01611,Hydroxychloroquine
,23138518,Cmax,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [ml],197.6,150361,DB01611,Hydroxychloroquine
,23138518,Cmax,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [ml],199.0,150362,DB01611,Hydroxychloroquine
,23138518,AUC0-24,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [h·ml],2460.1,150363,DB01611,Hydroxychloroquine
,23138518,AUC0-24,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [h·ml],2468.3,150364,DB01611,Hydroxychloroquine
above,32438446,Cmax /EC90 ratio,Only 14 of the 56 analyzed drugs achieved a Cmax /EC90 ratio above 1.,Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438446/),,1,152820,DB01611,Hydroxychloroquine
,8562294,elimination half-life,"The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),h,457,153015,DB01611,Hydroxychloroquine
,8562294,elimination half-life,"The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),h,526,153016,DB01611,Hydroxychloroquine
,8562294,renal clearance,"Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),[1] / [h],4.61,153017,DB01611,Hydroxychloroquine
,8562294,renal clearance,"Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),[1] / [h],1.79,153018,DB01611,Hydroxychloroquine
,23425382,Apparent total clearance,Apparent total clearance of HCQ from blood was 316 (± 319) mL/min (mean (± standard deviation).,A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425382/),[ml] / [min],316,181982,DB01611,Hydroxychloroquine
,8068494,Maximum blood concentrations,"Maximum blood concentrations of (-)-(R)-hydroxychloroquine were higher than (+)-(S)-hydroxychloroquine after oral dosing (121 +/- 56 and 99 +/- 42 ng/ml, respectively, P = 0.009).",Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068494/),[ng] / [ml],121,183178,DB01611,Hydroxychloroquine
,8068494,Maximum blood concentrations,"Maximum blood concentrations of (-)-(R)-hydroxychloroquine were higher than (+)-(S)-hydroxychloroquine after oral dosing (121 +/- 56 and 99 +/- 42 ng/ml, respectively, P = 0.009).",Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068494/),[ng] / [ml],99,183179,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],-,185697,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.4,185698,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],6.8,185699,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.9,185700,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],9.1,185701,DB01611,Hydroxychloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],7.5,185702,DB01611,Hydroxychloroquine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32-35,191092,DB01611,Hydroxychloroquine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32,191093,DB01611,Hydroxychloroquine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4315-5027,191094,DB01611,Hydroxychloroquine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4398,191095,DB01611,Hydroxychloroquine
greater,7904547,elimination half-lives,Both drugs have reported elimination half-lives of greater than 1 month.,Clinical pharmacokinetics of slow-acting antirheumatic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904547/),month,1,193639,DB01611,Hydroxychloroquine
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB01611,Hydroxychloroquine
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB01611,Hydroxychloroquine
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB01611,Hydroxychloroquine
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB01611,Hydroxychloroquine
,32393664,total plasma concentration,"Assuming the highest antiviral target exposure (total plasma concentration of 4.1 mg/l), all studies had about one-tenth the necessary concentration for in vitro viral inhibition.",Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393664/),[mg] / [l],4.1,198539,DB01611,Hydroxychloroquine
,12959287,fraction absorbed,The mean (+/- s.d.) fraction absorbed estimated by the four methods was 0.64 +/- 0.14 after the tablet and 0.87 +/- 0.30 after the oral solution.,Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),,0.64,207324,DB01611,Hydroxychloroquine
,12959287,fraction absorbed,The mean (+/- s.d.) fraction absorbed estimated by the four methods was 0.64 +/- 0.14 after the tablet and 0.87 +/- 0.30 after the oral solution.,Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),,0.87,207325,DB01611,Hydroxychloroquine
,12959287,absorption half-life,"3. The mean (+/- s.d.) absorption half-life was 3.7 +/- 2.0 h for the tablet and 3.3 +/- 1.6 h for the solution, suggesting that absorption following the tablet dose was not rate-limited by dissolution.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,3.7,207326,DB01611,Hydroxychloroquine
,12959287,absorption half-life,"3. The mean (+/- s.d.) absorption half-life was 3.7 +/- 2.0 h for the tablet and 3.3 +/- 1.6 h for the solution, suggesting that absorption following the tablet dose was not rate-limited by dissolution.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,3.3,207327,DB01611,Hydroxychloroquine
,12959287,lag-time before absorption commenced,"The lag-time before absorption commenced in fed subjects (1.65 +/- 0.46 h) showed a significant three-fold increase over that reported previously in fasting subjects (0.63 +/- 0.33 h), but this difference is not likely to be of clinical significance.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,1.65,207328,DB01611,Hydroxychloroquine
,12959287,lag-time before absorption commenced,"The lag-time before absorption commenced in fed subjects (1.65 +/- 0.46 h) showed a significant three-fold increase over that reported previously in fasting subjects (0.63 +/- 0.33 h), but this difference is not likely to be of clinical significance.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,0.63,207329,DB01611,Hydroxychloroquine
,33558079,plasma concentration,HCQ doses ranged from 200 to 800mg/day administered for 1 to 11days and median HCQ plasma concentration was 151ng/mL.,Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),ng,151,213017,DB01611,Hydroxychloroquine
,33558079,CL/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],45.9,213018,DB01611,Hydroxychloroquine
,33558079,Vd/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],45.9,213019,DB01611,Hydroxychloroquine
,33558079,Vd/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),l,6690,213020,DB01611,Hydroxychloroquine
,33558079,elimination half-life (t1/2),The derived elimination half-life (t1/2) was 102h.,Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),h,102,213021,DB01611,Hydroxychloroquine
,33558079,CL/F,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],68,213022,DB01611,Hydroxychloroquine
,33558079,Vd/F,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),l,2440,213023,DB01611,Hydroxychloroquine
,33558079,t1/2,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),h,19.5,213024,DB01611,Hydroxychloroquine
,33558079,half maximal effective concentration,"Within 72h of HCQ initiation, only 16/104 (15.4%) COVID-19 patients had HCQ plasma levels above the in vitro half maximal effective concentration of HCQ against SARS-CoV-2 (240ng/mL).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[ng] / [ml],240,213025,DB01611,Hydroxychloroquine
,33089870,resolution factor,The resolution factor and RSD were 1.62 and 0.35% and in vitro data of both products met the USP requirements.,In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089870/),%,1.62,213853,DB01611,Hydroxychloroquine
,33089870,RSD,The resolution factor and RSD were 1.62 and 0.35% and in vitro data of both products met the USP requirements.,In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089870/),%,0.35,213854,DB01611,Hydroxychloroquine
,8866926,Maximum hydroxychloroquine blood concentration (Cmax,"Maximum hydroxychloroquine blood concentration (Cmax; range 135-422 ng ml-1) and time to maximum (tmax; range 1.5-7.0 h) for the three tablet doses showed significant differences between subjects (P < 0.009; between subject coefficients of variation (CVs) 34% and 27%, respectively).",Hydroxychloroquine relative bioavailability: within subject reproducibility. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866926/),[ng] / [ml],135-422,224472,DB01611,Hydroxychloroquine
,8866926,time to maximum (tmax,"Maximum hydroxychloroquine blood concentration (Cmax; range 135-422 ng ml-1) and time to maximum (tmax; range 1.5-7.0 h) for the three tablet doses showed significant differences between subjects (P < 0.009; between subject coefficients of variation (CVs) 34% and 27%, respectively).",Hydroxychloroquine relative bioavailability: within subject reproducibility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866926/),h,1.5-7.0,224473,DB01611,Hydroxychloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.05,228213,DB01611,Hydroxychloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.3,228214,DB01611,Hydroxychloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.69,228215,DB01611,Hydroxychloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.93,228216,DB01611,Hydroxychloroquine
,9647356,fraction unbound,The fraction unbound of the R- and S-HCQ were 49.4% and 50.5% lower in platelet rich plasma of arthritic rats compared to healthy rats.,Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),%,49,228217,DB01611,Hydroxychloroquine
,9647356,fraction unbound,The fraction unbound of the R- and S-HCQ were 49.4% and 50.5% lower in platelet rich plasma of arthritic rats compared to healthy rats.,Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),%,50,228218,DB01611,Hydroxychloroquine
,22878749,overall response rate,"One patient had a partial response to erlotinib/HCQ, for an overall response rate of 5% (95% confidence interval, 1-25).",A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22878749/),%,5,230952,DB01611,Hydroxychloroquine
,33378773,EC50,"The 25 mg BID inhalation dosing was predicted to lead to alveolar HCQ levels of 7 µM (above EC50 of ~1-5 µM), and small plasma levels of 0.18 µM (as compared to plasma levels of 3.22 µM after 200 mg BID oral dosing).",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1-5,240168,DB01611,Hydroxychloroquine
>,33378773,average,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1,240169,DB01611,Hydroxychloroquine
>,33378773,contact time,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1,240170,DB01611,Hydroxychloroquine
,33378773,contact time,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),h,0.5,240171,DB01611,Hydroxychloroquine
,21703945,flow rate,The flow rate was 300 μL/min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),[μl] / [min],300,246444,DB01611,Hydroxychloroquine
,21703945,ch,The chromatographic run time was 3 min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),min,3,246445,DB01611,Hydroxychloroquine
,21703945,run time,The chromatographic run time was 3 min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),min,3,246446,DB01611,Hydroxychloroquine
,10848718,area under the plasma concentration-time curve,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,65,256387,DB01611,Hydroxychloroquine
,10848718,maximal plasma concentrations,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,72,256388,DB01611,Hydroxychloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.31,259420,DB01611,Hydroxychloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.62,259421,DB01611,Hydroxychloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.71,259422,DB01611,Hydroxychloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.83,259423,DB01611,Hydroxychloroquine
,2058666,Rd,"Total exogenous glucose infusion required to maintain euglycemia significantly increased (1,792.6-2,040.1 mg.kg-1.330 min-1, P less than 0.05) due to an increase in Rd (2,348.0-2,618.9 mg.kg-1.330 min-1, P less than 0.01) without change in Ra.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[mg] / [kg·min],"2,348.0-2,618.9",262172,DB01611,Hydroxychloroquine
,2058666,Metabolic clearance rate,"Metabolic clearance rate of insulin decreased by 39% from 14.4 +/- 1.3 to 11.0 +/- 0.6 ml.kg-1.min-1 (P less than 0.01) at plasma insulin levels of 150-200 mU/l but not at levels of 2,000-3,000 mU/l.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[ml] / [kg·min],14.4,262173,DB01611,Hydroxychloroquine
,2058666,Metabolic clearance rate,"Metabolic clearance rate of insulin decreased by 39% from 14.4 +/- 1.3 to 11.0 +/- 0.6 ml.kg-1.min-1 (P less than 0.01) at plasma insulin levels of 150-200 mU/l but not at levels of 2,000-3,000 mU/l.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[ml] / [kg·min],11.0,262174,DB01611,Hydroxychloroquine
,31477360,heart rate,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],115,265920,DB01611,Hydroxychloroquine
,31477360,respirations,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],18,265921,DB01611,Hydroxychloroquine
,31477360,half-life,Serial concentrations demonstrated apparent first-order elimination with a half-life of 11.6 h.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265922,DB01611,Hydroxychloroquine
,31477360,apparent,The apparent 11.6 hour half-life of hydroxychloroquine was shorter than previously described.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265923,DB01611,Hydroxychloroquine
